What do systematic reviews say?

Antihypertensive agent vs placebo

Antihypertensive agent showed no clear difference in ipsilateral major or disabling stroke (not reported) compared with placebo (low certainty).

• Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
  RR 0.14 [0.02, 1.16]
  1 study · 793 participants
  Low

Antihypertensive agent vs placebo

Antihypertensive agent showed no clear difference in stroke‐related mortality (not reported) compared with placebo (low certainty).

• Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
  RR 0.57 [0.17, 1.94]
  1 study · 793 participants
  Low

Antihypertensive agent vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antihypertensive agent vs placebo

Antihypertensive agent may leads to lower progression of carotid stenosis (DUS/at beginning and end) compared with placebo (low certainty).

• Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
  RR 0.45 [0.23, 0.91]
  1 study · 129 participants
  Low

Antihypertensive agent vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antihypertensive agent vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Antihypertensive agent vs placebo

The review found no eligible studies for this question.

• Pharmacological interventions for asymptomatic carotid stenosis 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Intensive insulin therapy vs conventional insulin therapy

Intensive insulin therapy may leads to lower occurrence of CIP/CIM ‐ in total population randomised compared with conventional insulin therapy (low certainty).

• Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes only
  RR 0.7 [0.6, 0.82]
  2 studies · 2748 participants
  Low

Intensive insulin therapy vs conventional insulin therapy

Intensive insulin therapy probably leads to lower occurrence of CIP/CIM ‐ in screened population compared with conventional insulin therapy (moderate certainty).

• Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes only
  RR 0.65 [0.55, 0.77]
  2 studies · 825 participants
  Moderate

Intensive insulin therapy vs conventional insulin therapy

• Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2748 participants
  High

Intensive insulin therapy vs conventional insulin therapy

• Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 2748 participants
  High

Intensive insulin therapy vs conventional insulin therapy

Intensive insulin therapy showed no clear difference in death ‐ at 30 days after ICU admission, in total population randomised compared with conventional insulin therapy (high certainty).

• Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes only
  RR 0.94 [0.8, 1.1]
  2 studies · 2748 participants
  High

Intensive insulin therapy vs conventional insulin therapy

Intensive insulin therapy showed no clear difference in death ‐ at 180 days after ICU admission, in total population… compared with conventional insulin therapy (moderate certainty).

• Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes only
  RR 0.87 [0.76, 1]
  2 studies · 2748 participants
  Moderate

Intensive insulin therapy vs conventional insulin therapy

Intensive insulin therapy leads to higher serious adverse events, ‐ in total population randomised ‐… compared with conventional insulin therapy (high certainty).

• Interventions for preventing critical illness polyneuropathy and critical illness myopathy 2014 · Cochrane Headline outcomes only
  RR 6.27 [4.15, 9.49]
  2 studies · 2748 participants
  High

Pulsed high‐intensity laser vs Placebo (sham) laser therapy

Pulsed high‐intensity laser showed no clear difference in change in burn‐related pruritus Itch Severity Scale (ISS) ( compared with placebo laser (moderate certainty).

• Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Moderate

Pulsed high‐intensity laser vs Placebo (sham) laser therapy

The review found no eligible studies for this question.

• Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Pulsed high‐intensity laser vs Placebo (sham) laser therapy

Pulsed high‐intensity laser showed no clear difference in pain VAS ( compared with placebo laser (moderate certainty).

• Interventions for postburn pruritus 2024 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 49 participants
  Moderate

Intensive glycaemic control vs conventional glucose control

Intensive glycaemic control may leads to higher adverse events (Hypoglycaemia) compared with standard glycaemic control (low certainty).

• Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia 2017 · Cochrane Headline outcomes only
  RR 2.18 [1.52, 3.14]
  2 studies · 12931 participants
  Low

Intensive glycaemic control vs conventional glucose control

Intensive glycaemic control showed no clear difference in global cognitive function (defined as reduction of at least 3 points… compared with standard glycaemic control (moderate certainty).

• Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia 2017 · Cochrane Headline outcomes only
  RR 0.98 [0.88, 1.08]
  1 study · 11140 participants
  Moderate

Intensive glycaemic control vs conventional glucose control

• Effect of the treatment of Type 2 diabetes mellitus on the development of cognitive impairment and dementia 2017 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 2794 participants
  Moderate